Neurogenesis Ltd.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
Phase 2
Not yet recruiting
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Biological: NG01 - Autologous bone marrow derived human stromal cellsOther: Sodium Chloride 0.9%
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NeuroGenesis Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06961383
- Locations
- 🇺🇸
University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center - Neurology, Miami, Florida, United States
🇮🇱Hadassah University Hospital, Jerusalem, Israel
News
No news found